Q-omics provides the consensus-scored TOMM20L profile across patient tissues and cancer cell-line models. TOMM20L expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TOMM20L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TOMM20L RNA expression shows 18,809 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KIRC, and ACC as cancer lineages where TOMM20L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOMM20L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOMM20L survival associations across molecular data types. TOMM20L RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOMM20L RNA expression–survival associations across cancer types. High TOMM20L expression shows unfavorable associations in HNSC, but favorable associations in CESC, KIRC, OV, READ and MESO. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TOMM20L RNA expression.
This table summarizes TOMM20L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TOMM20L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOMM20L shows lower tumor expression in KIRC, THCA, LUSC, KIRP and BRCA and higher tumor expression in LIHC. The KIRC box plot shows higher TOMM20L RNA expression in normal versus tumor tissue (log2 FC = −0.583, t-test p < 0.001).
This table shows molecular features associated with TOMM20L in patient tissues and cancer cell lines. In patient samples, TOMM20L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TOMM20L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OVARY.
